Tag: Hyloris Pharmaceuticals SA

Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million (€0.2 million in 2020) Significant expansion of commercial footprint of Maxigesic® IV Tranexamic ...

Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million (€0.2 million in 2020) Significant expansion of commercial footprint of Maxigesic® IV Tranexamic ...

Miconazole-Domiphen Bromide (MCZ-DB) vaginal cream is a candidate product for the treatment of recurring vulvovaginal candidiasis (rVVC), which affects 10% of all women globallyTopline results anticipated in H2 2022 Liège, ...

Patient-friendly alternative to continuous IV administration – proven safety and efficacyTargeting orphan, late-stage heart failure indication with high unmet medical needs  Liège, Belgium – 8 October 2021 – Hyloris Pharmaceuticals ...